![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1687234
°³ÀÎ ½Äº° ½ÃÀå : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2025-2030³â)Human Identification - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) |
°³ÀÎ ½Äº° ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 9¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ÀÎ 2025-2030³â CAGR 11.64%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 15¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº COVID-19ÀÇ ÇÇÅ©¿¡ ¸¹Àº °³ÀÎ ½Äº° ¼ºñ½º, ƯÈ÷ ¹ýÀÇÇРȰµ¿¿¡ ÁöÀåÀ» ÀÔ¾ú±â ¶§¹®¿¡ °³ÀÎ ½Äº° ½ÃÀå¿¡ Å« ¿µÇâÀ» ÁÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 2¿ù Journal of Safety Science and ResilienceÁö¿¡ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é ¹üÁË ¹× Á¶Á÷¹üÁË, °¡Á¤Æø·Â, Å×·¯¸®Áò, °Å¸®¹üÁË, ¿Â¶óÀιüÁË, ºÒ¹ý½ÃÀå ¹× ¹Ð¼ö, ÀνŸŸÅ, ¾ß»ýµ¿¹° ¸Å¸Å, ³ë¿¹Á¦ ¹× °µµ¿Í Àýµµ µî ºÎÁ¤°æÁ¦´Â ÆÒµ¥¹Í ½Ã´ë¿¡ ±âÇϱ޼öÀûÀ¸·Î °¨¼ÒÇß½À´Ï´Ù. µû¶ó¼ ÆÒµ¥¹Í ±â°£ Áß ¹üÁË¿Í ¼ö»çÀÇ °¨¼Ò´Â ¹ýÀÇÇÐÀû °Ë»çÀÇ ¼ö¸¦ ÁÙÀÌ°í ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇß½À´Ï´Ù. ´õ¿íÀÌ Äڷγª19´Â ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ ±â¼ú¿¡ ¸î °¡Áö ȹ±âÀûÀÎ °³¹ßÀ» °¡Á®¿Ô°í, ´ë±Ô¸ð ¹é½Å Á¢Á¾°ú ÇÔ²² °¨¿°·üÀÌ Å©°Ô ¶³¾îÁ³±â ¶§¹®¿¡ Á¶»ç´ë»ó ½ÃÀåÀº Äڷγª19ÀÇ ¿µÇâ¿¡¼ ȸº¹µÇ¾î ¿¹Ãø ±â°£ µ¿¾È °ÇÀüÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù.
ÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº °³ÀÎ ½Äº° ±â¼ú¿¡ ÀÖ¾î¼ÀÇ ±â¼úÁøº¸ Áõ°¡ ¹× Á¤ºÎÀÇ ´Ù¾çÇÑ ´ëó¿Í Áö¿øÀÔ´Ï´Ù. °³ÀÎ ½Äº°¿¡ ÀÇÇÑ ±â¼úÀû Áøº¸´Â ¼¼°è¸¦ º¸´Ù ¾ÈÀüÇÏ°Ô ¸¸µé±â À§ÇØ ¸Å¿ì Áß¿äÇϸç, ÀÌ·¯ÇÑ ±â¼úÀº ¹üÁËÀÚÀÇ ½Ä¿¡ ÀÇÇÑ °ÍÀ̱⠶§¹®¿¡ °úÇмö»ç¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. DNA ÇÁ·ÎÆÄÀϸµÀ» À§ÇÑ »õ·Î¿î ±â¼ú°ú ±â¼úÀº ¸Å³â °è¼Ó ÁøÈÇϰí ÀÖ½À´Ï´Ù. 2022³â 5¿ù, PromegaÀÇ Spectrum CE SystemÀº ijÇÊ·¯¸® Àü±â¿µµ¿(CE) ÀåÄ¡ ½ÃÀå¿¡ »õ·Î¿î ¼±ÅÃÁö¸¦ µµÀÔÇß½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ¹ýÀÇÇÐ ºÐ¼®ÀÚ°¡ ¼îÆ® ÅÄ´ý ¸®ÇÇÆ®(STR) ºÐ¼®À» ÀÌ¿ëÇØ »ùÇÃÀ» ó¸®ÇÏ´Â ¹æ¹ý¿¡¼ ½ºÄÉÁÙ¸µ °úÁ¦¸¦ ÇØ¼ÒÇϰí ÁÖ¿ä º¥´õÀÇ Äɹ̽ºÆ®¸®¸¦ Áö¿øÇÔÀ¸·Î½á ºñÇÒ µ¥ ¾ø´Â À¯¿¬¼ºÀ» ±âÀçÇϰí ÀÖ½À´Ï´Ù. Çü»ç »ç°ÇÀ̳ª µ¥ÀÌÅͺ£À̽º »ç°Ç¿¡ ÀÖ¾î¼ÀÇ °³ÀÎ ½Äº°¿¡, ¿öÅ© Ç÷ο츦 ¼Æ÷Æ®Çϴ ijÇÊ·¯¸® Àü±â ¿µµ¿(CE) ÀåÄ¡¿¡ »õ·Î¿î ¿É¼ÇÀÌ ´õÇØÁ³½À´Ï´Ù.
°Ô´Ù°¡ ´Ù¾çÇÑ »ê¾÷¿¡¼ °³ÀÎ ½Äº°¿¡ ÀÇÇÑ ÀáÀçÀûÀÎ °¡´É¼º°ú ¼ö¿äÀÇ °íÁ¶·ÎºÎÅÍ, Àü¼¼°èÀÇ Á¤ºÎ°¡ ÀÌ ºÎ¹®¿¡ ´ëÇÑ Áö¿øÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù ¸ß½ÃÄÚÀÇ ¾Èµå·¹½º ¸¶´©¿¤ ·ÎÆä½º ¿Àºê¶óµµ¸£ ´ëÅë·É(AMLO)Àº °³ÀÎ ½Äº°À» À§ÇÑ ±¹¸³ ¼¾ÅÍ ¼³¸³À» ½ÂÀÎÇß½À´Ï´Ù.
°Ô´Ù°¡ ½ÃÀå ÁøÃâ ±â¾÷ÀÌ ½Ç½ÃÇÏ´Â Á¦ÈÞ³ª Á¦Ç° ¹ß¸Å µîÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºêµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é, 2021³â 6¿ù, QIAGEN N.V.´Â »÷µð¿¡ÀÌ°í¿¡ °ÅÁ¡À¸·Î ÇÏ´Â °³ÀÎ ½Äº°¿¡ ÀÇÇÑ ½ºÆä¼È¸®½ºÆ® Verogenth¿ÍÀÇ »ó¾÷È ÆÄÆ®³Ê½ÊÀ» ¸®Æ÷Æ®Çß½À´Ï´Ù. 2022³â 3¿ù ¸ß½ÃÄÚÀÇ ¾Èµå·¹½º ¸¶´©¿¤ ·ÎÆä½º ¿Àºê¶óµµ¸£ ´ëÅë·É(AMLO)Àº °³ÀÎ ½Äº°À» À§ÇÑ ±¹¸³ ¼¾ÅÍ ¼³¸³À» ½ÂÀÎÇß½À´Ï´Ù. 2022³â 3¿ù, ARUP Laboratories´Â Â÷¼¼´ë ½ÃÄö½º °Ë»ç °á°ú¸¦ ´õ ³ªÀº, ´õ ½Å¼ÓÇÏ°Ô ¸¸µé±â À§ÇÑ »õ·Î¿î ¹ÙÀÌ¿À ÀÎÆ÷¸Åƽ½º Ç÷§Æû, ¼±ÁøÀû ¹ÙÀÌ¿À ÀÎÆ÷¸Åƽ½º ÆÄÀÌÇÁ¶óÀΰú ºÐ¼® Ç÷§ÆûÀÎ Rio¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Rio´Â ARUPÀÇ ±âÁ¸ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ±â´ÉÀ» È®´ëÇØ º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô µ¥ÀÌÅ͸¦ Àü¼ÛÇÔÀ¸·Î½á ÀÓ»óÀǵéÀÌ °Ë»ç °á°ú¸¦ º¸´Ù ½Å¼ÓÇÏ°Ô ºÐ¼®ÇÏ°í º¸´Ù ³ªÀº ÀÇ·á ÆÇ´ÜÀ» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. µû¶ó¼ °³ÀÎ ½Äº° ºÎ¹®¿¡¼ ÀÌ È¸»çÀÇ È°µ¿Àº Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» ²ø¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ¿Í °°ÀÌ Á¶»çÇÑ ½ÃÀ强ÀåÀº »ó±â ¿äÀο¡ ±âÀÎÇÏ¸ç ¿¹Ãø±â°£ µ¿¾È ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ±â±¸ ºñ¿ë°ú ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·ÀÌ ½ÃÀå ¼ºÀå¿¡ ¹æÇذ¡ µÉ ¼ö ÀÖ½À´Ï´Ù.
°³ÀÎ ½Äº°Àº ¹ýÀÇÇÐ, ºÎ¸ð¿Í ÀÚ½Ä °¨Á¤, ÀçÇØ ÇÇÇØÀÚ ½Äº°, ÀηùÇÐ µî¿¡¼ ³Î¸® ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç, DNA ºÐ¼® ¹× ÇÁ·ÎÆÄÀϸµÀº ÀÌ ºÎ¹®ÀÇ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¼¼°è ¹üÁËÀ²ÀÇ Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
À¯Àü °øÇРȸ»ç°¡ Á¾»çÇÏ´Â ÀüÇüÀûÀÎ ¹ýÀÇÇÐ ¼ºñ½º´Â Ç÷ûÇаú DNA ºÐ¼®À» Æ÷ÇÔÇÑ ¿©·¯ Ãâó¿¡¼ ÃàÀû µÈ µ¥ÀÌÅ͸¦ °¡Áö°í ÀÖÀ¸¸ç, ºÎ°Ë°ú ¼ö¼úÀÇ Á¶Á÷ »ùÇÃ, Èð¾îÁø Ç÷ÈçÀÇ Âû°ú»ó, »Ñ¸®ÀÖ´Â ¸ð¹ß µî ´Ù¾çÇÑ Ãâó¿¡¼ DNA¸¦ ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù. ¹ÙÀÌ¿À Å×Å©³î·ÎÁö¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â ±â¾÷Àº, Çü»ç »ç¹ý °ü·Ã ¼ºñ½º¿¡µµ Á¾»çÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù ÇÁ·Î¸Þ°¡ÀÇ ½ºÆåÆ®·³ CE SystemÀÌ Ãâ½ÃµÆ½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº 5»ö, 6»ö, 8»ö STR ºÐ¼® ÈÇаú ȣȯµÇ¸ç ¹ýÀÇÇÐ ½ÇÇè½Ç¿¡¼ °³ÀÎ ½Äº°¿¡ »ç¿ëµË´Ï´Ù. ÀÌó·³ Áøº¸´Â ºÎ¹® ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡ 2021³â 10¿ù Àεµ Á¤ºÎ´Â ¿©¼º°ú ¾Æµ¿ÀÇ ¼ºÀû ÇÐ´ë »ç°Ç¿¡ ´ëÇÑ Nirbhaya ü°è ÇÏ, ¹³¹ÙÀÌ, ³ª±×Ǫ¸£, Ǫ³×¿¡ 3°³ÀÇ ½Å¼ÓÇÑ DNA °Ë»ç À¯´ÖÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹üÁË °Ç¼öÀÇ Áõ°¡¿Í ¼¼°è Á¤ºÎÀÇ ´ëó°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹üÁË °Ç¼ö Áõ°¡¿¡ ÀÇÇØ °¨½Ä ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Áõ°¡ÀÇ Àϵµ¸¦ µû¸£°í ÀÖÀ¸¸ç, °¨½Ä ŰƮ³ª °¨½Ä ¼ºñ½º¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â °³ÀÎ ½Äº° ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ºÏ¹ÌÀÇ °³ÀÎ ½Äº° ½ÃÀåÀº °³ÀÎ ½Äº° ½Ã½ºÅÛÀÇ ±â¼úÀû Áøº¸¿¡ ´õÇØ, DNA ºÐ¼®¿¡ °É¸®´Â ½Ã°£°ú ºñ¿ëÀ» »è°¨ÇÏ´Â ¼ö¿ä Áõ°¡, ÀÌ ³ª¶ó¿¡¼ ¹ýÀÇÇп¡ ´ëÇÑ ÀÌ¿ë Áõ°¡¿¡ ÀÇÇØ ¿¹Ãø ±â°£ Áß¿¡ ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
¹Ì±¹ Á¤ºÎ·ÎºÎÅÍÀÇ °úÇÐ ¼ö»ç¸¦ Áö¿øÇϱâ À§ÇÑ ÀÚ±ÝÀº Áõ°¡Çϰí ÀÖ¾î À̰ÍÀÌ ÀÌ Áö¿ªÀÇ ¼ºÀåÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â, »ç¹ýºÎ »ç¹ý ÇÁ·Î±×·¥±¹(OJP)Àº ¹üÁË ¿¬±¸¼Ò¿¡ ÀÚ±ÝÀ» Á¦°øÇϰí, ¿¬±¸¸¦ Áö¿øÇϰí, DNA ¹é·Î±×¸¦ °¨¼Ò½Ã۰í, ¹ý ÁýÇà ±â°üÀÌ ½ÇÁ¾ÀÚ¸¦ ƯÁ¤ÇÏ´Â °ÍÀ» Áö¿øÇϱâ À§ÇØ, ÃÑ 2¾ï 1,000¸¸ ´Þ·¯ ÀÌ»óÀÇ »óÀ» ¼ö¿©Çß½À´Ï´Ù. °Ô´Ù°¡ ¹Ì±¹¿¡¼´Â ¹ýÀÇÇÐÀ» ¸ñÀûÀ¸·Î ÇÑ °ü°ø¼¿¡ ÀÇÇÑ °³ÀÎ ½Äº° ½Ã½ºÅÛ ±â¼úÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ, ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 8¿ù ´º¿å½Ã °¨ÂûÀǹ«¿øÀº Â÷¼¼´ë ½ÃÄö½º »ç¿ëÀ» ½ÂÀÎÇß°í, ±¹¹æºÎ´Â ÀÌ¹Ì Á¦2Â÷ ¼¼°è´ëÀü°ú Çѱ¹ÀüÀï, º£Æ®³²Àü ½Ã½ÅÀÇ ½Å¿øÀ» È®ÀÎÇÏ´Â µ¥ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ, °ü°ø¼¿¡ ÀÇÇÑ Á¦Ç°À̳ª ¼ºñ½ºÀÇ Ã¤¿ëÀ̳ª, °³ÀÎ ½Äº° ¼ºñ½º °³¹ßÀ» À§ÇÑ ÀÚ±Ý ¿øÁ¶°¡, ÀÌ ³ª¶óÀÇ ½ÃÀå °³Ã´À» ÁöÁöÇϰí ÀÖ½À´Ï´Ù.
°Ô´Ù°¡ ºÏ¹Ì ±¹°¡ÀÇ ÃÖ±Ù µ¿ÇâÀº Á¶»çµÈ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 2¿ù ANDECorporationÀº Áï³³ °¡´ÉÇÑ Rapid DNA booking management product suite¸¦ Ãâ½ÃÇß½À´Ï´Ù. °Ô´Ù°¡ 2022³â 3¿ù¿¡´Â Ancestry DNA°¡ Áö¸®Àû È®´ë Àü·«À¸·Î ¸ß½ÃÄÚ¿¡ Ãâ½ÃµÇ¾ú½À´Ï´Ù. ÀÌ ½ÃÀÛÀ¸·Î ¸ß½ÃÄÚ °í°´Àº 150¸¸ ¸í ÀÌ»óÀÇ ¸ß½ÃÄڰ踦 Æ÷ÇÔÇÑ ¼¼°è ÃÖ´ëÀÇ ¼ÒºñÀÚ DNA ´ëÁ¶ ³×Æ®¿öÅ©¿Í ¹ÎÁ· ÃßÁ¤ ¹× ±âŸ ¾×¼¼½º¸¦ Æ÷ÇÔÇÑ ¿ÏÀüÇÑ Á¶»ó DNA ±â´É ¼¼Æ®¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù. ÀÌó·³ ÀÌ Áö¿ª ±¹°¡µéÀÇ ÃÖ±Ù Áøº¸°¡ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
µû¶ó¼ ¾Õ¼ ¾ð±ÞÇÑ ¿äÀεé·ÎºÎÅÍ Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀº ºÏ¹Ì¿¡¼ ¿¹ÃøµË´Ï´Ù.
°³ÀÎ ½Äº° ½ÃÀåÀº Àû´çÇÑ °æÀï »óÅ¿¡ ÀÖ½À´Ï´Ù. »ó´çÇÑ ¼öÀÇ ±â¾÷ÀÌ Á¸ÀçÇÏ°í ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¦Ç° Çõ½Å°ú ÷´Ü ±â¼ú °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ °³¹ß Ȱµ¿Àº ½ÃÀå ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. ¼¼°èÀÇ °³ÀÎ ½Äº° ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷À¸·Î´Â Promega Corporation, AUTOGEN INC, Thermo Fisher Scientific Inc, Verogen Inc, Laboratory Corporation of America Holdings, Hamilton Company, Qiagen NV, ANDE Corporation, GENETEK Biopharma GmbH, Bio-Rad Laboratories, Inc. µîÀÌ ÀÖ½À´Ï´Ù.
The Human Identification Market size is estimated at USD 0.90 billion in 2025, and is expected to reach USD 1.57 billion by 2030, at a CAGR of 11.64% during the forecast period (2025-2030).
The COVID-19 pandemic had a significant impact on the human identification market as many human identification services were hampered during the peak of COVID-19, especially forensic activities. For instance, according to the study published in the Journal of Safety Science and Resilience in February 2022, crime, and illicit economies, such as organized crime, domestic violence, terrorism, street crime, online crime, illegal markets and smuggling, human and wildlife trafficking, slavery, robberies, and burglaries decreased exponentially during the pandemic era. Thus, a decrease in crimes and investigations during the pandemic reduced the number of forensic tests, impeding the market's growth. Moreover, COVID-19 led to some revolutionary developments in the polymerase chain reaction technology and as the infection rate decreased significantly along with large-scale vaccination, the studied market was expected to recover from the COVID-19 effect and have healthy growth over the forecast period.
The market is driven by an increase in technological advancement in human identification technology, and various government initiatives and supports. There is the rapid growth of technological advancements in human identification that is highly important to make the world more secure and these techniques are extensively used in forensics for the identification of criminals. There are new techniques and technologies for DNA profiling continue to evolve every year. In May 2022, Promega's Spectrum CE System introduced a new alternative in a market capillary electrophoresis (CE) instrument. The instrument provides forensic analysts with unrivalled flexibility in how they process samples using short tandem repeat (STR) analysis by eliminating scheduling challenges and supporting chemistry from key vendors. Human identification in criminal casework and database cases now has a new option for capillary electrophoresis (CE) instruments to support their workflow.
Additionally, governments around the world have increased their support for the field due to the potential and rising demand for human identification in various industries. For instance, in March 2022, Mexican President Andres Manuel Lopez Obrador (AMLO) approved the formation of a National Center for Human Identification.
Furthermore, the strategic initiatives such as collaborations and product launches undertaken by the market players contribute to the market growth. For instance, in June 2021, QIAGEN N.V. reported a commercialization partnership with San Diego-based human identification specialist Verogenthat will provide customers of both companies with superior tools and comprehensive support for human identification (HID) workflows in their laboratories. Further, in March 2022, Mexican President Andres Manuel Lopez Obrador (AMLO) approved the formation of a National Center for Human Identification. In March 2022, ARUP Laboratories launched a new bioinformatics platform for better, faster next-generation sequencing test results, Rio, an advanced bioinformatics pipeline and analytics platform. Rio extends ARUP's existing cloud computing capabilities to transfer data more quickly and accurately, allowing clinicians to analyze test findings more quickly and make better medical decisions. Hence, the company's activities in the human identification segment are expected to boost the studied market growth.
Thus, the studied market growth is attributed to the above mentioned factors, and the market is expected to grow significantly over the forecast period. However, the cost of instruments and the shortage of skilled professionals might hinder market growth.
Human identification is widely used in forensics, paternity testing, disaster victim identification, and anthropology, with DNA analysis/profiling being a key tool in this sector. The increasing crime rate across the globe is one of the major factors driving the growth of this segment.
In typical forensic services engaged by a genetic engineering company, there are data accumulated from several sources, including serology and DNA analysis, and profiling DNA from various sources, such as tissue samples from autopsy and surgery, scrapings from blood spatter, and hair with roots, among others. The biotechnology-based companies are also engaged in criminal justice-related services. For instance, in March 2022, the Spectrum CE System of Promega corporation was launched. This system is compatible with any 5-, 6- or 8-color STR analysis chemistry for use in forensic laboratories for human identification. Thus, the advances are expected to drive segment growth.
Moreover, In October 2021, the Indian Government launched three fast-track DNA testing units in Mumbai, Nagpur, and Pune under the Nirbhaya scheme for women and child sexual abuse cases. This growing number of crime and government initiatives globally are expected to drive segment growth.
The demand for identification technology is rising continuously due to the growing rate of crimes is boosting the need for forensic kits and services, enhancing the segment growth over the forecast period.
North America holds a significant share of the human identification market. The North American human identification market is expected to grow during the forecast period owing to the technological advancements in the human identification system coupled with the increasing demand for reducing the time and cost of DNA analysis and growing use in forensics in this country.
The funding from the United States government for supporting forensics is rising, which is responsible for the growth of the region. For instance, in 2021, the Department of Justice's Office of Justice Programs (OJP) granted awards totalling more than USD 210 million to fund crime laboratories, support research, decrease DNA backlogs, and help law enforcement identify missing persons. Further, the increasing adoption of human identification system techniques by government offices in the United States for forensic purposes is also expected to propel the market's growth. Such as, in August 2020, the New York City medical examiner's office approved to use next-generation sequencing, which the Department of Defense is already using to identify remains from World War II and the Korean and Vietnam Wars. Thus, the adoption of products and services by government offices and funding for the development of human identification services is bolstering the market growth in the country.
Moreover, the recent development in the countries across North America is the major factor driving the studied market growth. For example, in February 2021, ANDE corporation launched the Rapid DNA booking management product suite, which is available for immediate delivery. Moreover, in March 2022, Ancestry DNA company was launched in Mexico as a geographical expansion strategy. This launch provides customers in Mexico access to the world's largest consumer DNA match network, which includes over 1.5 million of Mexican descent and the full ancestry DNA feature set, including ethnicity estimates and other access. Thus, the recent advances in the countries across the region are driving market growth.
Therefore, owing to the previously mentioned factors, the growth of the studied market is predicted in the North American region.
The human identification market is moderately competitive. There has been a presence of a considerable number of companies that are significantly contributing to the market growth. Product innovation and ongoing development activities for developing advanced technologies have been helping the growth of the market. Key market players operating in the global human identification market include Promega Corporation, AUTOGEN INC, Thermo Fisher Scientific Inc., Verogen Inc., Laboratory Corporation of America Holdings, Hamilton Company, Qiagen NV, ANDE Corporation, GENETEK Biopharma GmbH, and Bio-Rad Laboratories, Inc.